415 Capital Announces €150 Million Second Fund and Key Appointments to Investment Committee to Support Breakthrough and Life-Saving Medical Innovation

The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. "We are incredibly grateful for the trust our limited partners continue to place in us. Their support highlights the significant clinical impact and value of our portfolio,"said Frederik Groenewegen...

MUNICH, 29/10/2024 (informazione.it - comunicati stampa - salute e benessere)

The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon.

said , Co-Founder and General Partner at 415 Capital.

In conjunction with the successful fundraising, also announced the appointments of and to its Investment Committee.

commented Groenewegen

 is a leading venture capital firm specializing in medical technology investments across Europe , the U.S., and Israel . Headquartered in Munich, Germany , the firm manages nearly $200 million in assets and focuses on clinical-stage innovations addressing cardiovascular and neurovascular diseases, the leading causes of death and disability globally and the top drivers of healthcare costs. Additionally, 415 Capital selectively invests in neuromodulation, medical robotics, and companies innovating at the intersection of patient monitoring, medical imaging, and Artificial Intelligence (AI).

Over the past five years, portfolio companies have attracted over €600 million ( $650 million ) in follow-on financing from leading life science venture capital firms and corporate strategic investors. Some notable portfolio companies include and  .

By leveraging a global network of Key Opinion Leaders and partnerships with world-renowned hospitals and clinical research institutions across Europe , the US, and Israel , 415 Capital provides its portfolio companies with unparalleled strategic support. Over the years, the firm's team has backed more than 50 medical technology startups, whose products are now utilized by physicians to treat hundreds of thousands of patients annually.

Contacts: Linus Rieder , +49 (0) 171 729 3092

View original content: https://www.prnewswire.co.uk/news-releases/415-capital-announces-150-million-second-fund-and-key-appointments-to-investment-committee-to-support-breakthrough-and-life-saving-medical-innovation-302290000.html